Susquehanna International Group, LLP Ac Immune Sa Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Ac Immune Sa stock. As of the latest transaction made, Susquehanna International Group, LLP holds 12,300 shares of ACIU stock, worth $43,665. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,300

Previous 149,900 91.79%

Holding current value

$43,665

Previous $598,000 92.31%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.77 - $3.38 $10,761 - $13,131	-3,885 Reduced 5.15%	71,487 $203,000
Q2 2023 Aug 11, 2023	BUY	$1.85 - $3.4 $116,498 - $214,104	62,972 Added 507.84%	75,372 $223,000
Q1 2023 May 16, 2023	SELL	$2.13 - $2.49 $101,209 - $118,314	-47,516 Reduced 79.3%	12,400 $29,000
Q4 2022 Feb 14, 2023	BUY	$1.72 - $3.12 $103,055 - $186,937	59,916 New	59,916 $122,000
Q2 2022 Aug 15, 2022	SELL	$2.35 - $4.47 $22,470 - $42,742	-9,562 Reduced 36.62%	16,546 $60,000
Q1 2022 May 16, 2022	SELL	$3.5 - $5.16 $197,396 - $291,018	-56,399 Reduced 68.36%	26,108 $104,000
Q4 2021 Feb 14, 2022	BUY	$4.83 - $7.56 $117,943 - $184,607	24,419 Added 42.04%	82,507 $408,000
Q1 2021 May 17, 2021	SELL	$5.32 - $8.96 $397,031 - $668,684	-74,630 Reduced 56.23%	58,088 $442,000
Q4 2020 Feb 16, 2021	BUY	$4.47 - $5.58 $361,886 - $451,751	80,959 Added 156.42%	132,718 $686,000
Q3 2020 Nov 16, 2020	BUY	$4.78 - $9.06 $192,691 - $365,226	40,312 Added 352.16%	51,759 $253,000
Q2 2020 Aug 14, 2020	BUY	$6.57 - $8.3 $75,206 - $95,010	11,447 New	11,447 $77,000

Others Institutions Holding ACIU

# of Institutions

Shares Held

28.2M

Call Options Held

150K

Put Options Held

12.4K

View Full List

About AC Immune SA

Ticker ACIU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,413,504
Market Cap $296M
Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...

More about ACIU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Ac Immune Sa Transaction History